TMCI logo

TREACE MEDICAL CONCEPTS INC

TMCINASDAQ
πŸ† #3408 by market capUS Equity
$911.84β–² $64.47 (+7.07%)
Simulated price
πŸ””
Track TMCI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 7.1%
7dβ–² 19787.5%
14dβ–² 19765.8%
30dβ–² 19446.4%
ytdβ–² 37118.0%
1yβ–² 13448.9%
🏦Market Cap
$291M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+1.6%
Slowing
πŸ“ŠGross Margin
79.5%
High
πŸ’΅FCF Margin
-12.2%
Thin
βš–οΈP/S Ratio
1.4x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$898.49 – $926.41
52-Week Range
$1.17 – $7.08
Volume
$3.28B
Avg Volume
$3.09B
Shares Outstanding
64.9M
Next Earnings
Nov 12, 2026

Fundamentals Snapshot

Annual Revenue
$213M
Last Q Revenue
$45M
P/E Ratio
-4.8
P/S Ratio
1.4x
EPS (TTM)
$-0.91
Dividend Yield
0.00%
Dilution (1yr)
+2.4%

Why Investors Own TMCI

  • βœ“High-growth profile β€” revenue up +22.1% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 30% gross margin and 26% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TMCI logo

TREACE MEDICAL CONCEPTS INC

TMCI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$213Mβ–² +1.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.8%β–Ό βˆ’0.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$54Mβ–Ό βˆ’2.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$29Mβ–Ό βˆ’39.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
63.9Mβ–² +2.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$3Mβ–² +$55M YoY
StockOtter Β· stockotter.space

About TREACE MEDICAL CONCEPTS INC

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$1,018.32
β–² +11.7% Upside
High Target$1,226.79
Low Target$820.16
Based on 13 analysts

Latest News & Updates